ArticleClinical kidney journal2017
B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis.
Article in Clinical kidney journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis.Nature reviews. Rheumatology · 2026Guideline
- The efficacy of rituximab in the treatment of IgA vasculitis nephritis.Clinical and experimental medicine · 2024Pooled it
- Systematic Review and Meta-Analysis of Rituximab for Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children.Frontiers in pediatrics · 2021Pooled it
- The successful use of rituximab in children with IgA nephropathy and minimal change-like lesions: a case series.Renal failure · 2026Article
- Single-dose rituximab as induction therapy in adult IgA vasculitis with rapidly progressive glomerulonephritis: a case report with peripheral blood CD19⁺ B-cell monitoring.CEN case reports · 2026Article
- Tfh Cells in Henoch-Schönlein Purpura (IgA Vasculitis): Current Concept.Journal of immunology research · 2026Review
- Advances in multi-omics and therapeutic studies of Henoch-Schönlein purpura.Italian journal of pediatrics · 2025Review
- Targeting CD20 for B-cell Depletion in Autoimmune Kidney Disease: Next Generation.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Article
- Efficacy and safety of rituximab in primary IgA nephropathy: a retrospective study.Clinical and experimental nephrology · 2025Article
- Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial.Drug design, development and therapy · 2025Article
- IgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment.Journal of clinical medicine · 2024Review
- Navigating Adult-Onset IgA Vasculitis-Associated Nephritis.Life (Basel, Switzerland) · 2024Review
- Drugs in Development to Treat IgA Nephropathy.Drugs · 2024Review
- Advances in the treatment of IgA nephropathy with biological agents.Chronic diseases and translational medicine · 2024Review
- Efficacy and safety of biologic agents for IgA nephropathy: A protocol for systematic review and meta-analysis.PloS one · 2024Article
- Clinical advances in immunotherapy for immune-mediated glomerular diseases.Clinical and experimental medicine · 2023Review
- A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP).Clinical rheumatology · 2023Review
- Immune abnormalities in IgA nephropathy.Clinical kidney journal · 2023Review
- IgA vasculitis with nephritis: update of pathogenesis with clinical implications.Pediatric nephrology (Berlin, Germany) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproximately 30% of adult patients with immunoglobulin A (IgA) nephropathy (IgAN) or IgA vasculitis with nephritis (IgAVN) develop end-stage renal disease during long-term follow-up. In particular, patients with nephritic-nephrotic syndrome have an increased risk of rapid progression. Conventional immunosuppressive therapy with corticosteroids (CSs) may be insufficient for disease control and is associated with a number of side effects. Rituximab (RTX) has been shown to be well tolerated and effective in a range of glomerular diseases, but there is little information on its therapeutic potential in IgAN. The humanized anti-CD20 monoclonal antibody ofatumumab (OFAB) may be an alternative drug for patients intolerant or unresponsive to RTX, but so far there is no report on its use in IgAVN or IgAN.
methodsWe describe clinical outcomes after 17-22 months in four adult patients with biopsy-confirmed IgAVN or IgAN treated with RTX or OFAB as well as CS soon after diagnosis. All presented with nephritic-nephrotic syndrome and one had crescentic IgAN. Rebiopsy was performed in two cases.
resultsRTX and OFAB were well tolerated. Albuminuria was <250 mg/day in three patients at last evaluation and two regained normal renal function. In all cases, renal function improved after therapy. In one patient with severe IgA vasculitis, rebiopsy showed disappearance of subendothelial but not mesangial immune complexes. In the case with crescentic IgAN, rebiopsy after 9 months showed no active necrotic lesions.
conclusionsB cell-depleting therapy may be an alternative treatment for patients with IgAN or IgAVN and nephritic-nephrotic syndrome. A possible CS-sparing effect should be further evaluated in randomized controlled clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.